Mounjaro vs Ozempic: the short UK answer
For weight loss in the UK, Mounjaro vs Ozempic is not a perfect like-for-like comparison. Mounjaro is a tirzepatide medicine licensed for weight management as well as type 2 diabetes in eligible patients. Ozempic is a semaglutide medicine licensed for type 2 diabetes. It may affect appetite and weight, but Ozempic is not the UK semaglutide product licensed for weight management. Wegovy is. [1][2][3]
That distinction matters because many searches compare the brand names people have heard of, rather than the most clinically accurate treatment options. This guide compares Mounjaro and Ozempic directly, then explains where Wegovy fits for UK weight-loss decisions.
|
Question
|
Mounjaro
|
Ozempic
|
What this means for UK weight loss
|
|
Active ingredient
|
Tirzepatide
|
Semaglutide
|
They are different medicines, not two brands of the same drug.
|
|
Medicine class
|
Dual GIP and GLP-1 receptor agonist
|
GLP-1 receptor agonist
|
Mounjaro works through two incretin pathways; Ozempic works through GLP-1.
|
|
UK licensed use
|
Type 2 diabetes and weight management in eligible adults
|
Type 2 diabetes
|
For weight loss, Ozempic is the wrong UK brand comparison. Wegovy is the semaglutide weight-management brand.
|
|
Average weight-loss evidence
|
Tirzepatide generally shows greater average weight loss in trials
|
Semaglutide also supports weight loss, but Ozempic dosing and licensing are diabetes-focused
|
A prescriber should compare suitability, not just headline averages.
|
|
Common side effects
|
Nausea, diarrhoea, vomiting, constipation and other gastrointestinal symptoms
|
Nausea, diarrhoea, vomiting and other gastrointestinal symptoms
|
Tolerance can decide whether a medicine is usable, even when average efficacy looks strong.
|
|
Best for
|
A person who is clinically suitable for tirzepatide after assessment
|
A person with type 2 diabetes where semaglutide is clinically suitable
|
There is no safe universal winner.
|
What is the main difference between Mounjaro and Ozempic?
The main difference is the active ingredient and receptor action. Mounjaro contains tirzepatide, which activates GIP and GLP-1 receptors. Ozempic contains semaglutide, which activates the GLP-1 receptor. Both are incretin-based medicines, but Mounjaro is not simply a stronger version of Ozempic. It is a different medicine with a different mechanism. [1][2]
GLP-1 activity helps regulate blood glucose, slows gastric emptying and can increase fullness. Tirzepatide also acts on the GIP receptor. The Mounjaro SmPC states that tirzepatide lowers body weight in people with type 2 diabetes and in people who are overweight or have obesity, with reduced food intake contributing to weight loss. [1]
Is Mounjaro better than Ozempic for weight loss?
On average, tirzepatide has shown greater weight reduction than semaglutide in relevant trials. In SURPASS-2, a 40-week trial in people with type 2 diabetes, tirzepatide produced greater reductions in body weight and HbA1c than semaglutide 1 mg. This was a diabetes trial, not a UK weight-loss treatment comparison, and semaglutide 1 mg reflects Ozempic-style diabetes dosing rather than Wegovy-style obesity dosing. [4]
A more relevant obesity comparison is tirzepatide versus semaglutide at obesity-treatment doses. In SURMOUNT-5, adults with obesity but without type 2 diabetes had an average weight reduction of 20.2% with tirzepatide and 13.7% with semaglutide at 72 weeks. This supports the view that tirzepatide often produces greater average weight loss, but it still does not mean Mounjaro is automatically better for every patient. [5]
A medicine can look stronger in trial averages and still be the wrong choice for an individual. Previous side effects, gallbladder history, pancreatitis risk, diabetic eye disease, pregnancy plans, other medicines, affordability and long-term support all affect suitability.
Is Ozempic approved for weight loss in the UK?
Ozempic is not licensed for weight management in the UK. Its UK SmPC lists use for adults with insufficiently controlled type 2 diabetes as an adjunct to diet and exercise. [2]
This does not mean semaglutide has no role in weight management. Wegovy also contains semaglutide and is licensed in the UK for weight management in eligible adults with obesity or overweight plus at least one weight-related comorbidity. [3] The MHRA has also stated that Saxenda, Wegovy and Mounjaro are the GLP-1/GIP-related products licensed for weight management in the UK. [8]
So, if the question is “Mounjaro vs Ozempic for weight loss in the UK”, the honest answer is: Mounjaro is a licensed weight-management option for eligible adults; Ozempic is a diabetes medicine; Wegovy is the semaglutide medicine to compare for weight management.
Which is better for type 2 diabetes?
Both Mounjaro and Ozempic are used for type 2 diabetes, and both can improve blood glucose when prescribed appropriately. In SURPASS-2, tirzepatide was superior to semaglutide 1 mg for HbA1c reduction in people with type 2 diabetes over 40 weeks. [4]
That does not replace individual diabetes care. Existing medicines, hypoglycaemia risk, kidney function, eye disease, cardiovascular history and treatment goals can change the right choice. People taking insulin or a sulfonylurea need particular prescriber input because GLP-1 or GIP/GLP-1 medicines can affect hypoglycaemia risk when combined with glucose-lowering treatment. [2][3]
Mounjaro vs Ozempic side effects
The most common side effects with both medicines are gastrointestinal. Mounjaro product information lists gastrointestinal disorders as the most frequently reported adverse reactions, with nausea, diarrhoea and vomiting tending to occur more during dose escalation and reduce over time. Ozempic product information also lists gastrointestinal disorders, including nausea, diarrhoea and vomiting, as the most frequently reported adverse reactions. [1][2]
Side effects are not just an inconvenience. Persistent vomiting or diarrhoea can contribute to dehydration, and dehydration can sometimes become medically serious. The MHRA advises patients using GLP-1 medicines to stay hydrated and seek professional advice if concerned about side effects. [8]
Seek urgent medical advice if you develop severe, persistent abdominal pain, especially if it spreads to your back or comes with nausea and vomiting. The MHRA strengthened warnings in 2026 because acute pancreatitis can occur with GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists, including rare severe cases.
|
Symptom or situation
|
Why it matters
|
What to do
|
|
Severe, persistent abdominal pain, especially spreading to the back, with or without nausea or vomiting
|
Possible pancreatitis
|
Seek urgent medical advice. Do not take further doses until clinically advised.
|
|
Repeated vomiting, diarrhoea, dizziness, very dark urine or inability to keep fluids down
|
Possible dehydration or kidney strain
|
Contact your prescriber urgently; use urgent care if symptoms are severe.
|
|
Sudden loss of vision or marked visual change while using semaglutide
|
Semaglutide product information includes urgent referral advice for possible NAION
|
Seek urgent eye assessment or urgent medical advice.
|
|
Swelling of the face, lips, tongue or throat, breathing difficulty or collapse
|
Possible serious allergic reaction
|
Call 999 or seek emergency help.
|
|
Yellowing of the skin or eyes, fever, severe right-sided upper abdominal pain or pale stools
|
Possible gallbladder or liver-related problem
|
Contact urgent medical care or your prescriber promptly.
|
Mounjaro vs Ozempic cost in the UK
There is no single reliable answer to “which is cheaper?” because the practical UK comparison is distorted by licensing. Ozempic is a type 2 diabetes medicine. Mounjaro is licensed for weight management in eligible adults. Wegovy is the semaglutide brand licensed for weight management. Comparing Ozempic prices with Mounjaro weight-loss prices can therefore be misleading.
For private treatment, compare the full monthly cost rather than the headline pen price. That includes dose stage, consultation, clinical review, delivery, support, cancellation terms and whether the provider can manage side effects or switching safely. For NHS weight-management treatment, NICE guidance applies eligibility criteria and local implementation rules. [6][7]
Can you switch from Ozempic to Mounjaro?
Some people can switch between incretin-based medicines, but this should only happen after prescriber review. Do not overlap, combine or self-convert doses between Ozempic and Mounjaro. They are different medicines, and dose strengths are not directly interchangeable.
A prescriber will usually need to know your current dose, last injection date, side effects, weight change, diabetes status, other medicines and any previous problems such as pancreatitis, gallbladder disease or severe gastrointestinal symptoms. Switching may involve restarting at a lower dose or delaying treatment if side effects are not controlled.
How to decide which option is right for you
A useful treatment decision is not “which medicine has the biggest average result?” It is “which option is suitable, tolerable, affordable and safe enough for me to use consistently under clinical supervision?”
- why you are considering treatment: weight management, type 2 diabetes, or both;
- your BMI, weight-related health conditions and previous weight-loss attempts;
- your history of pancreatitis, gallbladder disease, severe reflux, gastroparesis, kidney problems or diabetic eye disease;
- any insulin, sulfonylurea or other glucose-lowering medicines;
- pregnancy plans, breastfeeding or recent surgery;
- previous nausea, vomiting, constipation, diarrhoea or dehydration on similar medicines;
- the realistic monthly cost and whether the support model is strong enough for long-term treatment.
This is also why a simple “Mounjaro is better” answer is not enough. Trial averages can guide the discussion, but your prescriber should assess the risk-benefit balance for your circumstances.
Mounjaro and Ozempic are related but different medicines. Mounjaro contains tirzepatide and acts on GIP and GLP-1 receptors. Ozempic contains semaglutide and acts on GLP-1 receptors. Trial evidence generally favours tirzepatide for average weight loss, but the UK licensing position is the key practical point: Mounjaro is licensed for weight management in eligible adults, while Ozempic is licensed for type 2 diabetes. For semaglutide weight-loss treatment, the UK comparison is Wegovy, not Ozempic.
The right decision should be made with a qualified prescriber, especially if you have diabetes, take glucose-lowering medicines, have had significant side effects, or are considering switching from one medicine to another.
